Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Maria Gavriatopoulou; Efstathios Kastritis; Marie‐Christine Kyrtsonis; Theodoros P. Vassilakopoulos; Μαρία Ρούσσου; Despina Fotiou; Magdalini Migkou; Maria Mpakiri; Anna Tasidou; Evangelos Terpos; Meletios A Dimopoulos

doi:10.1080/10428194.2016.1233541

Related publications

Article2003

Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide

Meletios A Dimopoulos, George Hamilos, Eleni Efstathiou, Ioannis Siapkaras, Charis Matsouka, Dimitra Gika, Vassiliki Grigoraki, Christos Papadimitriou, Dimitrios Mitsibounas, Nikolaos Anagnostopoulos

Article1993

Fludarabine therapy in Waldenström's macroglobulinemia

Meletios A Dimopoulos, Susan O’Brien, Hagop M. Kantarjian, Sherry Pierce, Kay Delasalle, B Barlogie, Raymond Alexanian, Michael J. Keating

Article2005

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Meletios A Dimopoulos, Athanasios K. Anagnostopoulos, Maria Christina Kyrtsonis, Efstathios Castritis, Athanasios Bitsaktsis, Gerassimos A. Pangalis

Letter2015

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie‐Christine Kyrtsonis, Μαρία Ρούσσου, Evdoxia Hadjiharissi, Argiris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A Dimopoulos

Article2018

Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos